When does Stelara (ustekinumab) patent protection end?
Stelara, an injectable medication for conditions like Crohn's disease and plaque psoriasis, faces patent expirations that could allow for the introduction of biosimilar versions. Information from DrugPatentWatch.com indicates that various patents protecting ustekinumab have expiration dates in the coming years, with some key patents expiring around 2023 and others extending into the later 2020s [1].
What are biosimilars and how do they relate to Stelara?
Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an already approved biological medicine (the reference product) [2]. For Stelara, biosimilar manufacturers are preparing to launch their versions once patent exclusivity for the originator drug lapses, potentially increasing patient access and lowering costs.
Which companies are developing Stelara biosimilars?
Several pharmaceutical companies are actively developing biosimilar versions of ustekinumab. These include companies such as Amgen, Fresenius Kabi, and Samsung Bioepis, among others who have publicly announced their development programs or filed regulatory applications [1].
What is the timeline for Stelara biosimilar launches?
The precise launch timeline for Stelara biosimilars depends on patent litigation outcomes and regulatory approvals in different regions. While some patents have already expired or are nearing expiration, others may be subject to legal challenges. Successful navigation of these processes by biosimilar developers will determine when their products become available to patients [1].
How do biosimilars differ from generics?
Biosimilars are similar to generic drugs in that they offer a lower-cost alternative to an originator product. However, due to the complex nature of biological drugs, biosimilars are not exact copies like generic drugs are of small-molecule medications. Instead, they are highly similar in terms of safety, efficacy, and quality, with no significant differences for clinical use [2].
What are the potential impacts of Stelara biosimilars?
The introduction of Stelara biosimilars is expected to foster competition, which could lead to reduced treatment costs for healthcare systems and patients. This increased competition may also drive innovation and improve patient access to important therapies for chronic conditions [2].